BiVictriX Therapeutics plc announced that Non-Executive Director, Iain Ross, is stepping down from the board with immediate effect to pursue other interests. A Nomination Committee, consisting of Non-Executive Directors and chaired by Dr. Michael Kauffman, will initiate a search for Iain's replacement with appropriate skills to help move the Company forward, in anticipation of its first clinical trials in patients with Acute Myeloid Leukaemia.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
10.1 GBX | -8.18% | -12.17% | -3.81% |
Apr. 17 | Bivictrix granted FDA orphan drug status for rare cancer treatment | AN |
Apr. 17 | BiVictriX Wins US FDA's Orphan Drug Status for Blood Cancer Treatment | MT |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-3.81% | 11.54M | |
+52.96% | 55.07B | |
-1.33% | 41.79B | |
+44.47% | 40.22B | |
-7.59% | 28.17B | |
+12.69% | 26.28B | |
-21.20% | 18.93B | |
+7.45% | 13.03B | |
+30.48% | 12.26B | |
+26.13% | 12.21B |
- Stock Market
- Equities
- BVX Stock
- News BiVictriX Therapeutics Plc
- Bivictrix Therapeutics plc Announces Resignation of Iain Ross from the Board